Back to results
US 10,328,062 B2Granted
Biomarkers and use of MET inhibitor for treatment of cancer
AssigneeAmgen Inc.
InventorsSean Caenepeel, Angela Coxon, Zhiqiang Du, Paul Hughes, Robert Loberg, Gataree Ngarmchamnanrith, Beate Sable
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of therapeutic treatment of cancer using selective tyrosine kinase inhibitors and cancer biomarkers, such as MET amplification and high Met expression for patient selection.
Claims9
A method of treating a patient diagnosed with gastric cancer, wherein a sample of tumor cells obtained from the patient:
- (i) has the presence of focal amplification of the MET gene;
- and
- (ii) does not have a mutation at the KRAS gene;
- wherein the presence of focal amplification of the MET gene is defined by FISH as a ratio of MET gene copy number to chromosome 7 copy number;
- and
- wherein the ratio is 2 or higher,
- the method comprising administering to the patient an amount of
- (6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one) effective to provide a therapeutic benefit.
5 more elements
Dependencies are inferred from the claim text.